Medicine and Dentistry
Human Immunodeficiency Virus
100%
COVID-19
61%
Hepatitis C Virus
48%
Invasive Aspergillosis
39%
Antiretroviral Therapy
30%
Lung Aspergillosis
26%
Cohort Analysis
25%
Antiviral Drug
21%
Immunocompromised Patient
20%
Prospective Cohort Study
19%
Aspergillus
18%
Men Who Have Sex with Men
16%
Antiviral Therapy
16%
Infection
14%
Hepatitis C
14%
Prevalence
13%
Antivirus Agent
13%
Coronavirinae
13%
Reinfection
12%
B Cell
12%
Diagnosis
12%
Galactomannan
12%
Omicron Coronavirus Variant
11%
Catheter Infection
11%
Intensive Care Unit
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Messenger RNA
10%
Pyrrole
10%
Antifungal Therapy
10%
Diseases
9%
Immunogenicity
9%
Nonnucleoside Reverse Transcriptase Inhibitor
9%
COVID-19 Vaccine
9%
Dolutegravir
9%
Doravirine
9%
Infectious Disease
9%
Retrospective Cohort Study
9%
Bronchoalveolar Lavage Fluid
9%
Observational Study
8%
Convalescence
8%
Monotherapy
8%
Highly Active Antiretroviral Therapy
8%
Neutralizing Antibody
8%
Ritonavir
7%
Cell Count
7%
Proteinase Inhibitor
6%
T Cell
6%
Virus
6%
Monoclonal Antibody Therapy
6%
Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
85%
Invasive Aspergillosis
45%
Diseases
38%
Cohort Study
35%
Hepatitis C Virus
34%
Coronavirinae
33%
Lung Aspergillosis
28%
Posaconazole
23%
Immunocompromised Patient
20%
Prospective Cohort Study
19%
SARS Coronavirus
19%
Dolutegravir
18%
Antiviral Drug
18%
Pharmacokinetics
15%
Antivirus Agent
14%
Pyrrole
14%
Randomized Controlled Trial
14%
Immunogenicity
14%
Voriconazole
14%
Aspergillus
11%
Hepatitis C
11%
Galactomannan
11%
Infection
11%
Placebo
10%
Lamivudine
10%
Doravirine
9%
Clinical Trial
9%
Drug-Drug Interaction
9%
Monotherapy
8%
Chemotherapy
8%
Monoclonal Antibody
8%
Reinfection
8%
Elimination
7%
Prevalence
7%
Ritonavir
7%
Acute Myeloid Leukemia
6%
Myelodysplastic Syndrome
6%
Adverse Event
6%
Tenofovir Disoproxil
6%
Malignant Neoplasm
6%
Antibiotics
6%
Virus Hepatitis
6%
Human Immunodeficiency Virus 1
6%
Proteinase Inhibitor
6%
Neutralizing Antibody
5%
Hyperimmune Globulin
5%
Viral Clearance
5%
Sodium Valproate
5%
Tolerability
5%
Therapeutic Drug Monitoring
5%
Immunology and Microbiology
COVID-19
60%
Blood Plasma
49%
Human Immunodeficiency Virus
40%
Severe Acute Respiratory Syndrome Coronavirus 2
35%
Immunogenicity
18%
Neutralizing Antibody
15%
B Cell
12%
Bronchoalveolar Lavage Fluid
11%
Omicron Coronavirus Variant
10%
Human Immunodeficiency Virus 1
10%
Immunocompromised Patient
9%
Booster Dose
9%
Aspergillus
9%
Hepatitis C Virus
9%
T Cell
8%
Titer
7%
Antibody Titer
7%
CD4 Lymphocyte Count
6%
Hepatitis C
6%
Polymerase Chain Reaction
6%
Viral Clearance
5%
Monoclonal Antibody
5%
Monoclonal Antibody Therapy
5%